HRP20151382T1 - Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar - Google Patents
Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar Download PDFInfo
- Publication number
- HRP20151382T1 HRP20151382T1 HRP20151382TT HRP20151382T HRP20151382T1 HR P20151382 T1 HRP20151382 T1 HR P20151382T1 HR P20151382T T HRP20151382T T HR P20151382TT HR P20151382 T HRP20151382 T HR P20151382T HR P20151382 T1 HRP20151382 T1 HR P20151382T1
- Authority
- HR
- Croatia
- Prior art keywords
- weight
- total weight
- amount
- pharmaceutical preparation
- preparation
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title claims 8
- 238000009472 formulation Methods 0.000 title claims 2
- 239000013543 active substance Substances 0.000 title 1
- XGXNTJHZPBRBHJ-UHFFFAOYSA-N n-phenylpyrimidin-2-amine Chemical class N=1C=CC=NC=1NC1=CC=CC=C1 XGXNTJHZPBRBHJ-UHFFFAOYSA-N 0.000 title 1
- 239000000825 pharmaceutical preparation Substances 0.000 claims 13
- 238000002360 preparation method Methods 0.000 claims 12
- 239000004094 surface-active agent Substances 0.000 claims 8
- -1 diglycerides Chemical class 0.000 claims 5
- LCPGCGAJBOWMIP-UHFFFAOYSA-N n-[4-methyl-3-[(4-pyridin-3-ylpyrimidin-2-yl)amino]phenyl]-3,5-bis(trifluoromethyl)benzamide Chemical compound C1=C(NC=2N=C(C=CN=2)C=2C=NC=CC=2)C(C)=CC=C1NC(=O)C1=CC(C(F)(F)F)=CC(C(F)(F)F)=C1 LCPGCGAJBOWMIP-UHFFFAOYSA-N 0.000 claims 5
- 235000014113 dietary fatty acids Nutrition 0.000 claims 4
- 229930195729 fatty acid Natural products 0.000 claims 4
- 239000000194 fatty acid Substances 0.000 claims 4
- 239000004615 ingredient Substances 0.000 claims 4
- 239000002904 solvent Substances 0.000 claims 4
- NLZUEZXRPGMBCV-UHFFFAOYSA-N Butylhydroxytoluene Chemical compound CC1=CC(C(C)(C)C)=C(O)C(C(C)(C)C)=C1 NLZUEZXRPGMBCV-UHFFFAOYSA-N 0.000 claims 3
- 150000004665 fatty acids Chemical class 0.000 claims 3
- CVHZOJJKTDOEJC-UHFFFAOYSA-N saccharin Chemical group C1=CC=C2C(=O)NS(=O)(=O)C2=C1 CVHZOJJKTDOEJC-UHFFFAOYSA-N 0.000 claims 3
- 229940081974 saccharin Drugs 0.000 claims 3
- 235000019204 saccharin Nutrition 0.000 claims 3
- 239000000901 saccharin and its Na,K and Ca salt Substances 0.000 claims 3
- 229920003171 Poly (ethylene oxide) Polymers 0.000 claims 2
- CZBZUDVBLSSABA-UHFFFAOYSA-N butylated hydroxyanisole Chemical compound COC1=CC=C(O)C(C(C)(C)C)=C1.COC1=CC=C(O)C=C1C(C)(C)C CZBZUDVBLSSABA-UHFFFAOYSA-N 0.000 claims 2
- 235000019264 food flavour enhancer Nutrition 0.000 claims 2
- 235000003599 food sweetener Nutrition 0.000 claims 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 2
- 239000003765 sweetening agent Substances 0.000 claims 2
- 206010028980 Neoplasm Diseases 0.000 claims 1
- 229920002675 Polyoxyl Polymers 0.000 claims 1
- 229920002685 Polyoxyl 35CastorOil Polymers 0.000 claims 1
- 229940053200 antiepileptics fatty acid derivative Drugs 0.000 claims 1
- 239000003963 antioxidant agent Substances 0.000 claims 1
- 230000003078 antioxidant effect Effects 0.000 claims 1
- 235000019568 aromas Nutrition 0.000 claims 1
- OGBUMNBNEWYMNJ-UHFFFAOYSA-N batilol Chemical class CCCCCCCCCCCCCCCCCCOCC(O)CO OGBUMNBNEWYMNJ-UHFFFAOYSA-N 0.000 claims 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 201000011510 cancer Diseases 0.000 claims 1
- 239000004359 castor oil Substances 0.000 claims 1
- 235000019438 castor oil Nutrition 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 125000005456 glyceride group Chemical group 0.000 claims 1
- ZEMPKEQAKRGZGQ-XOQCFJPHSA-N glycerol triricinoleate Natural products CCCCCC[C@@H](O)CC=CCCCCCCCC(=O)OC[C@@H](COC(=O)CCCCCCCC=CC[C@@H](O)CCCCCC)OC(=O)CCCCCCCC=CC[C@H](O)CCCCCC ZEMPKEQAKRGZGQ-XOQCFJPHSA-N 0.000 claims 1
- LHGVFZTZFXWLCP-UHFFFAOYSA-N guaiacol Chemical compound COC1=CC=CC=C1O LHGVFZTZFXWLCP-UHFFFAOYSA-N 0.000 claims 1
- 239000007902 hard capsule Substances 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 150000004668 long chain fatty acids Chemical class 0.000 claims 1
- 238000000034 method Methods 0.000 claims 1
- 239000003921 oil Substances 0.000 claims 1
- 235000019198 oils Nutrition 0.000 claims 1
- ZQPPMHVWECSIRJ-KTKRTIGZSA-N oleic acid Chemical compound CCCCCCCC\C=C/CCCCCCCC(O)=O ZQPPMHVWECSIRJ-KTKRTIGZSA-N 0.000 claims 1
- 239000008180 pharmaceutical surfactant Substances 0.000 claims 1
- 229940057847 polyethylene glycol 600 Drugs 0.000 claims 1
- 150000003839 salts Chemical class 0.000 claims 1
- 150000004671 saturated fatty acids Chemical class 0.000 claims 1
- 235000003441 saturated fatty acids Nutrition 0.000 claims 1
- 230000001225 therapeutic effect Effects 0.000 claims 1
- 239000006163 transport media Substances 0.000 claims 1
- 150000003626 triacylglycerols Chemical class 0.000 claims 1
- 150000004670 unsaturated fatty acids Chemical group 0.000 claims 1
- 235000015112 vegetable and seed oil Nutrition 0.000 claims 1
- 239000008158 vegetable oil Substances 0.000 claims 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4866—Organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Epidemiology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Dispersion Chemistry (AREA)
- Physiology (AREA)
- Nutrition Science (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Preparation (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Agricultural Chemicals And Associated Chemicals (AREA)
- Plural Heterocyclic Compounds (AREA)
Claims (15)
1. Farmaceutski pripravak za oralnu primjenu koji sadrži:
a) terapijski djelotvornu količinu (3,5-bis trifluorometil)-N-[4-metil-3-(4-piridin-3il-pirimidin-2il amino) fenil] benzamida (NRC-AN-019) ili njegove farmaceutske prihvatljive soli;
b) lipofilnu fazu;
c) najmanje jedan farmaceutski prihvatljiv surfaktant; i
d) farmaceutski prihvatljivo otapalo koje je mješljivo s vodom.
2. Farmaceutski pripravak prema zahtjevu 1, naznačen time, što
- sastojak (a) je prisutan u količini od 0,1 do 20 % težine relativne ukupnoj težini pripravka, poželjno od 0,25 do 10 % težine relativne ukupnoj težini pripravka;
- sastojak (b) je prisutan u količini od 10 do 75 % težine relativne ukupnoj težini pripravka, poželjno od 12,5 do 65 % težine relativne ukupnoj težini pripravka;
- sastojak (c) je prisutan u količini od 4 do 70 % težine relativne ukupnoj težini pripravka, poželjno od 8 do 60 % težine relativne ukupnoj težini pripravka; i
- sastojak (d) je prisutan u količini od 5 do 30 % težine relativne ukupnoj težini pripravka, poželjno od 5,5 do 25 % težine relativne ukupnoj težini pripravka.
3. Farmaceutski pripravak prema zahtjevu 1 ili 2 koji se sastoji od oblika I, oblika II ili oblika III polimorfa izuma NRC-AN-019.
4. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što se lipofilna faza sastoji od triglicerida, diglicerida, monoglicerida, masne kiseline, derivata masne kiseline ili njihove smjese, pri čemu je masna kiselina poželjno dugolančana masna kiselina, poželjnije od C12 do C22 masna kiselina, još poželjnije mononezasićena C12-20 masna kiselina koja je u tečnom stanju na sobnoj temperaturi, najpoželjnije (Z)-9-oktadekaenska kiselina.
5. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što su ostaci C18 nezasićene masne kiseline prisutni u lipofilnoj fazi u količini od najmanje 20 % težine, poželjno najmanje 40 % težine relativne ukupnoj težini lipofilne faze, i/ili su ostaci zasićene masne kiseline prisutni u lipofilnoj fazi u količini od 50 % težine ili manje na osnovi ukupne težine lipofilne faze.
6. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što se najmanje jedan surfaktant sastoji od glavnog surfaktanta i jednog ili više pomoćnih surfaktanata, pri čemu je pomoćni surfaktant tipično prisutan u količino od 2 do 60 % težine relativne ukupnoj težini pripravka, poželjno od 5 do 45 % težine relativne ukupnoj težini pripravka, a pri čemu pomoćni surfaktant poželjno sadrži polioksil glicerid, poželjnije kaprilokaproil polioksiglicerid.
7. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što najmanje jedan surfaktant sadrži polioksietilen glikolizirano biljno ulje, poželjno polioksietilen glikolizirano ricinusovo ulje, najpoželjnije polioksil 35 ricinusovo ulje.
8. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što otapalo koje je mješljivo s vodom djeluje kao prijenosni medij za NRC-AN-019.
9. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, naznačen time, što otapalo koje je mješljivo u vodi jeste α-hidroksi-ω-hidroksi poli(oksi-1, 2-ehanediil) derivat, poželjno polietilen glikol 600.
10. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, koji dalje sadrži antioksidans koji je poželjno odabran iz butil hidroksianizola, butil hidroksitoluena i njihove smjese, poželjnije smjese butil hidroksianizola i butil hidroksitoluena u omjeru od 6:4 do 9:1, najpoželjnije smjese butil hidroksianizola i butil hidroksitoluena u omjeru od 7:3 do 8:2.
11. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva, koji dalje sadrži sredstvo za zaslađivanje i/ili sredstvo za poboljšanje okusa, pri čemu je sredstvo za zaslađivanje poželjno saharin, poželjnije saharin u količini od 0,1 težine do 10 % težine relativne ukupnoj težini u pripravku, najpoželjnije saharin u količini od 0,25 % težine do oko 5 % težine relativne ukupnoj težini pripravka, dok je sredstvo za poboljšanje okusa poželjno odabrano iz aroma na bazi ulja, bilo zasebnih ili u kombinaciji, pri čemu je sredstvo za poboljšanje okusa poželjno prisutno u količini od 0,1 težinskih postotaka do oko 10 težinskih postotaka relativnih ukupnoj težini pripravka, poželjnije od 0,25 težinskih postotaka do 1 težinski postotak relativan ukupnoj težini pripravka.
12. Farmaceutski pripravak prema bilo kojem od prethodnih zahtjeva koji se nalazi u obliku otopine, mekog gela ili formulacije u tvrdoj kapsuli.
13. Farmaceutski pripravak kao što je definirano u bilo kojem od prethodnih zahtjeva za primjenu u terapijskom liječenju tijela čovjeka ili životinje.
14. Farmaceutski pripravak kao što je definiranu u bilo kojem od zahtjeva 1 do 12 za primjenu u liječenju raka.
15. Postupak za dobivanje farmaceutskog pripravka kao što je definirano u bilo kojem od zahtjeva 1 do 12, koji se sastoji od
- primiješanja NRC-AN-019 s otapalom koje je mješljivo s vodom,
- dodavanja lipofilne faze,
- dodavanja surfaktanta i opcionalno dodatnog surfaktanta, i
- miješanja uz primjenu topline.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GB1103860.1A GB2488788B (en) | 2011-03-07 | 2011-03-07 | Oral formulation of phenylaminopyrymidine compound with enhanced bioavailability and pharmacological response |
| PCT/IB2011/001842 WO2012120328A1 (en) | 2011-03-07 | 2011-08-10 | Formulation comprising phenylaminopyrimidine derivative as active agent |
| EP11764851.9A EP2683381B1 (en) | 2011-03-07 | 2011-08-10 | Formulation comprising phenylaminopyrimidine derivative as active agent |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| HRP20151382T1 true HRP20151382T1 (hr) | 2016-02-12 |
Family
ID=43923331
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| HRP20151382TT HRP20151382T1 (hr) | 2011-03-07 | 2015-12-16 | Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar |
Country Status (32)
| Country | Link |
|---|---|
| US (1) | US9895367B2 (hr) |
| EP (1) | EP2683381B1 (hr) |
| JP (1) | JP5788534B2 (hr) |
| KR (1) | KR101767296B1 (hr) |
| CN (1) | CN103561742B (hr) |
| AP (1) | AP4076A (hr) |
| AU (1) | AU2011361921B2 (hr) |
| BR (1) | BR112013022930A2 (hr) |
| CA (1) | CA2829015C (hr) |
| CO (1) | CO6811851A2 (hr) |
| CY (1) | CY1116968T1 (hr) |
| DK (1) | DK2683381T3 (hr) |
| EA (1) | EA024610B1 (hr) |
| ES (1) | ES2554927T3 (hr) |
| GB (1) | GB2488788B (hr) |
| GE (1) | GEP20156410B (hr) |
| HR (1) | HRP20151382T1 (hr) |
| HU (1) | HUE025562T2 (hr) |
| IL (1) | IL228218A (hr) |
| MA (1) | MA35088B1 (hr) |
| MX (1) | MX339130B (hr) |
| MY (1) | MY158693A (hr) |
| NZ (1) | NZ614903A (hr) |
| PL (1) | PL2683381T3 (hr) |
| PT (1) | PT2683381E (hr) |
| RS (1) | RS54420B1 (hr) |
| SG (1) | SG193349A1 (hr) |
| SI (1) | SI2683381T1 (hr) |
| SM (1) | SMT201500235B (hr) |
| UA (1) | UA111074C2 (hr) |
| WO (1) | WO2012120328A1 (hr) |
| ZA (1) | ZA201306643B (hr) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP6896738B2 (ja) * | 2015-12-18 | 2021-06-30 | ナトコ ファーマ リミテッド | フェニルアミノピリミジン誘導体を含む医薬組成物 |
| WO2017115316A1 (en) * | 2015-12-29 | 2017-07-06 | Noivita S.R.L.S. | Lipophilic formulations |
| CN107184549B (zh) * | 2017-04-11 | 2020-11-20 | 江苏大学 | 一种尼达尼布自微乳制剂和其制成的软胶囊及制备方法 |
| CN107564610A (zh) * | 2017-10-20 | 2018-01-09 | 浙江中大元通特种电缆有限公司 | 一种陶瓷化硅橡胶绝缘护套不锈钢连锁铠装防火电缆 |
| PT3765024T (pt) | 2018-03-14 | 2024-02-19 | Kandy Therapeutics Ltd | Formulação farmacêutica inovadora que compreende antagonistas duplos dos recetores nk-1/nk-3 |
| WO2020151633A1 (en) * | 2019-01-25 | 2020-07-30 | Shenzhen Pharmacin Co., Ltd. | Pharmaceutical compositions |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9405304D0 (en) * | 1994-03-16 | 1994-04-27 | Scherer Ltd R P | Delivery systems for hydrophobic drugs |
| ES2219895T3 (es) * | 1997-07-29 | 2004-12-01 | PHARMACIA & UPJOHN COMPANY | Formulacion autoemulsionante para compuestos lipofilos. |
| US6248354B1 (en) | 1999-03-04 | 2001-06-19 | Allergan Sales, Inc. | Capsule system |
| US7232825B2 (en) * | 2003-05-02 | 2007-06-19 | Guoqing P Chen | Phenylaminopyrimidine derivatives and methods of use |
| EP1498143A1 (en) * | 2003-07-18 | 2005-01-19 | Aventis Pharma S.A. | Self-emulsifying and self-microemulsifying formulations for the oral administration of taxoids |
| SI1786799T1 (sl) * | 2004-09-09 | 2012-12-31 | Natco Pharma Limited | Novi derivati fenilaminopirimidina kot inhibitorji BCR-ABL kinaze |
| US20080103305A1 (en) * | 2006-10-26 | 2008-05-01 | Macdonald Peter | Process for the preparation of imatinib |
| EP1920767A1 (en) * | 2006-11-09 | 2008-05-14 | Abbott GmbH & Co. KG | Melt-processed imatinib dosage form |
| KR101697363B1 (ko) * | 2007-04-30 | 2017-01-17 | 인터자인 테크놀로지스, 인코포레이티드 | 소수성 제제를 캡슐화하기 위해 사용되는 혼합 입체화학을 가지는 혼성 블록 공중합체 미셀 |
| KR20100126464A (ko) | 2008-03-04 | 2010-12-01 | 낫코 파마 리미티드 | 페닐아미노 피리미딘 유도체의 결정 형태 |
| US8067422B2 (en) * | 2008-03-04 | 2011-11-29 | Natco Pharma Limited | Crystal form of phenylamino pyrimidine derivatives |
| KR20160129109A (ko) * | 2008-05-23 | 2016-11-08 | 아미라 파마슈티칼스 인코포레이티드 | 5-리폭시게나아제 활성화 단백질 억제제 |
-
2011
- 2011-03-07 GB GB1103860.1A patent/GB2488788B/en not_active Expired - Fee Related
- 2011-08-10 NZ NZ614903A patent/NZ614903A/en not_active IP Right Cessation
- 2011-08-10 AP AP2013007128A patent/AP4076A/en active
- 2011-08-10 US US14/003,445 patent/US9895367B2/en not_active Expired - Fee Related
- 2011-08-10 WO PCT/IB2011/001842 patent/WO2012120328A1/en active Application Filing
- 2011-08-10 HU HUE11764851A patent/HUE025562T2/en unknown
- 2011-08-10 GE GEAP201113254A patent/GEP20156410B/en unknown
- 2011-08-10 PL PL11764851T patent/PL2683381T3/pl unknown
- 2011-08-10 BR BR112013022930A patent/BR112013022930A2/pt not_active IP Right Cessation
- 2011-08-10 ES ES11764851.9T patent/ES2554927T3/es active Active
- 2011-08-10 CN CN201180069095.7A patent/CN103561742B/zh not_active Expired - Fee Related
- 2011-08-10 MY MYPI2013003265A patent/MY158693A/en unknown
- 2011-08-10 SI SI201130592T patent/SI2683381T1/sl unknown
- 2011-08-10 SG SG2013067319A patent/SG193349A1/en unknown
- 2011-08-10 MX MX2013010160A patent/MX339130B/es active IP Right Grant
- 2011-08-10 DK DK11764851.9T patent/DK2683381T3/en active
- 2011-08-10 JP JP2013557180A patent/JP5788534B2/ja not_active Expired - Fee Related
- 2011-08-10 KR KR1020137026440A patent/KR101767296B1/ko active IP Right Grant
- 2011-08-10 PT PT117648519T patent/PT2683381E/pt unknown
- 2011-08-10 CA CA2829015A patent/CA2829015C/en not_active Expired - Fee Related
- 2011-08-10 AU AU2011361921A patent/AU2011361921B2/en not_active Ceased
- 2011-08-10 RS RS20150787A patent/RS54420B1/en unknown
- 2011-08-10 EA EA201391280A patent/EA024610B1/ru not_active IP Right Cessation
- 2011-08-10 EP EP11764851.9A patent/EP2683381B1/en active Active
- 2011-10-08 UA UAA201310715A patent/UA111074C2/uk unknown
-
2013
- 2013-09-01 IL IL228218A patent/IL228218A/en active IP Right Grant
- 2013-09-04 ZA ZA2013/06643A patent/ZA201306643B/en unknown
- 2013-09-09 MA MA36236A patent/MA35088B1/fr unknown
- 2013-10-04 CO CO13236457A patent/CO6811851A2/es unknown
-
2015
- 2015-09-29 SM SM201500235T patent/SMT201500235B/xx unknown
- 2015-11-26 CY CY20151101069T patent/CY1116968T1/el unknown
- 2015-12-16 HR HRP20151382TT patent/HRP20151382T1/hr unknown
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| HRP20151382T1 (hr) | Formulacija koja sadrži derivat fenilaminopirimidina kao djelatnu tvar | |
| RU2621615C2 (ru) | Фармацевтическая композиция, содержащая луликоназол | |
| JP2012524771A5 (hr) | ||
| JP6738120B2 (ja) | 外用医薬組成物 | |
| KR102162901B1 (ko) | 위장관을 따라 약물을 표적화 방출하기 위한 pH 감응성 담체, 그로부터의 조성물, 및 이들의 제조 및 사용 방법 | |
| JP2013100317A5 (hr) | ||
| BRPI0710611A2 (pt) | composições farmacêuticas e seus usos | |
| RU2015136849A (ru) | Композиции, содержащие 15-он эпк, и способы их применения | |
| HRP20160446T1 (hr) | Farmaceutski pripravci koji sadrže derivat kamptotecina | |
| JP2016512828A5 (hr) | ||
| JP5286086B2 (ja) | 還元型補酵素ｑ１０及びリゾレシチンを含有する組成物 | |
| JP2015516418A5 (hr) | ||
| MX2020002238A (es) | Composiciones de acidos grasos y ester de acido graso autoformadores de micelas y su uso en el tratamiento de patologias. | |
| JP2021506967A (ja) | 痛風を治療するための尿酸一ナトリウムの溶解 | |
| JP2022051835A (ja) | テクトリゲニン－７－０－キシロシルグルコシドを含む女性更年期症状緩和用組成物 | |
| WO2018123906A1 (ja) | 外用組成物 | |
| CN111356450A (zh) | Pde5抑制剂的液体填充制剂 | |
| ES2888125T3 (es) | Composiciones y métodos de limpieza | |
| AU2017370664A1 (en) | Personal lubricant providing sequential multisensorial perceptions and articles incorporating such lubricant | |
| JP6503626B2 (ja) | 医薬組成物 | |
| JP6900189B2 (ja) | 外用組成物 | |
| JP7234268B2 (ja) | 外用組成物 | |
| JP2014513710A5 (hr) | ||
| JP2000053562A (ja) | 噴射用組成物 | |
| ES2406186B1 (es) | Emulsiones con derivados alquílicos del dihidroxibenceno. |